Introduction
============

Conjugation allows bacteria to transfer genetic material from one cell to another via cell to cell contact ([@B29]). It has been recognized as one of most important contributors for dissemination of antimicrobial resistance genes ([@B11]). Conjugative plasmids-transfer in Gram-negative bacteria requires the expression of transfer (*tra*) genes involved in DNA transfer and replication, and in mating pair formation ([@B17]). *tra* genes encode relaxases which are required for processing the DNA and accessory proteins, which are able to recognize the origin of transfer (*oriT*) and to cut the DNA molecule at the *nic* site ([@B26]). Plasmid-conjugation is primarily mediated by Type IV secretion systems (T4SSs), which are multi-protein complexes located in the membrane of the cell and which are able to support the donor and recipient mating-pair ([@B22]).

A substantial amount of data suggests that sub-inhibitory concentrations of antibiotics may significantly increase the conjugation transfer frequency both *in vitro* and in the animal gut ([@B9]; [@B39]; [@B42]; [@B4]; [@B20]; [@B2]; [@B30]). In our previous study, we designed an experimental setup for measurement of conjugation frequency in which we could separate conjugation rate from the power of selection by the antibiotics. We showed that the transfer frequency of the plasmid pTF2 in *Escherichia coli* MG1655 in an antibiotic free environment was increased significantly when the donor was pre-grown in broth containing cefotaxime (CTX) ([@B33]). However, the underlying mechanism remains to be determined.

TraF, an essential component of the *E. coli* T4SS, is responsible for the processing of pilus assembly, which is essential in the formation of mating apparatus and for conjugative plasmid transfer ([@B41]; [@B23]). Previous studies showed that modification of any region of *traF* abolished pilus synthesis, resulting in a loss of conjugative function ([@B28]). In the current study we used this gene fused to a *lacZ* reporter gene to identify genes not directly involved in the plasmid transfer mechanism and involved in the CTX-induced increased conjugative transfer of the ESBL encoding plasmid. We used a genetic screen, where random insertional mutagenesis was performed in *E. coli* MG1655/pTF2 with a *lacZ* reporter gene fused to the *traF* promoter on the plasmid. Our results identified six chromosomally encoded genes and one plasmid encoded gene involved in the CTX induced plasmid transfer mechanism. Such genes may be future targets to prevent antibiotic induced spread of resistance plasmids.

Materials and Methods
=====================

Bacterial Strains and Growth Conditions
---------------------------------------

Bacterial strains and plasmids used in this study are listed in [Table 1](#T1){ref-type="table"}. Luria-Bertani (LB) media was used in experiments for growth of bacteria. Bacterial strains were grown at 37°C except for strains containing the temperature sensitive plasmids, pKD46 and pCP20, which were grown at 30°C. When appropriate, media were supplemented with antibiotics (Sigma, Copenhagen, Denmark) including 20 mg/L gentamicin (Gem); 50 mg/L kanamycin (Kam); 25 mg/L chloramphenicol (Cap); 10 mg/L Trimethoprim (Tmp) and 2--512 mg/L cefotaxime (CTX). The β-galactosidase chromogenic indicator 5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-gal) was used at a concentration of 80 mg/L.

###### 

Bacterial strains and plasmids used in this study.

  **Strains**     **Genotype**                                                                       **References**
  --------------- ---------------------------------------------------------------------------------- ----------------
  MG1655/pTF2     *E. coli* MG1655 + *bla*~CTX--~*~M--~*~1~ containing IncI1 plasmid pTF2 (Amp^R^)   [@B25]
  J53-2           *E. coli*, Rif^R^                                                                  [@B3]
  ATCC^®^ 25922   *E. coli* Reference strain                                                         [@B12]
  GL100           MG1655/pTF2 Δ*traF*:*lacZ*, CTX^R^                                                 This work
  GL101           MG1655 *rfaH*:Tn5/pTF2 Δ*traF*:*lacZ*, CTX^R^, Tmp^R^                              This work
  GL102           MG1655 *yhiN*:Tn5/pTF2 Δ*traF*:*lacZ*, CTX^R^, Tmp^R^                              This work
  GL103           MG1655 *waaP*:Tn5/pTF2 Δ*traF*:*lacZ*, CTX^R^, Tmp^R^                              This work
  GL104           MG1655 *waaQ*:Tn5/pTF2 Δ*traF*:*lacZ*, CTX^R^, Tmp^R^                              This work
  GL105           MG1655 *gnd*:Tn5/pTF2 Δ*traF*:*lacZ*, CTX^R^, Tmp^R^                               This work
  GL106           MG1655 *pgl*:Tn5/pTF2 Δ*traF*:*lacZ*, CTX^R^, Tmp^R^                               This work
  GL107           MG1655/pTF2 Δ*traF*:*lacZ* IS*Ecp1*:Tn5, CTX^R^, Tmp^R^                            This work
  GL111           MG1655 Δ*rfaH*/pTF2, CTX^R^                                                        This work
  GL112           MG1655 Δ*yhiN*/pTF2, CTX^R^                                                        This work
  GL113           MG1655 Δ*waaP*/pTF2, CTX^R^                                                        This work
  GL114           MG1655 Δ*waaQ*/pTF2, CTX^R^                                                        This work
  GL115           MG1655 Δ*gnd*/pTF2, CTX^R^                                                         This work
  GL116           MG1655 Δ*pgl*/pTF2, CTX^R^                                                         This work
  GL117           MG1655/pTF2 ΔIS*Ecp1*, CTX^R^                                                      This work
  **Plasmids**                                                                                       
  pKD46           rep~pSC101~^ts^ Gem^R^ P*~*araBAD*~*γβ *exo*                                       [@B18]
  pKD4            rep~R6K~ γAmp^R^ FRT Kam^R^ FRT                                                    [@B16]
  pCP20           rep~pSC101~^ts^ Amp^R^ Cap^R^ *cI*857 λP~R~                                        [@B14]
  pCE36           rep~R6K~ γ Kam^R^ FRT lacZY t~his~                                                 [@B19]

Antimicrobial Susceptibility Testing
------------------------------------

The minimal inhibitory concentrations (MIC) of CTX was determined using the broth microdilution methods using 0--512 mg/L by 2-fold dilution increases, and using the control strain *E. coli* ATCC^®^ 25922 following the CLSI guidelines M100-S25 as previous described (Wayne and [@B15]).

Construction of *lacZ* Reporter Fusions
---------------------------------------

A LacZ reporter fusion MG1655/pTF2 Δ*traF*:*lacZ* was created using the λ Red recombination method as previously described ([@B16]; [@B19]). Using the primers traF-F and traF-R, a PCR fragment of the kanamycin cassette (Kam^R^) from plasmid pKD4 was amplified using Phusion^TM^ Hot Start II DNA polymerase (ThermoFisher Scientific) and purified using the GeneJET PCR Purification Kit (ThermoFisher Scientific) and the fragment was introduced into MG1655/pTF2 harboring pKD46 by electroporation, to exchange the *traF* gene with the kanamycin cassette. The kanamycin resistant cassette was removed using plasmid pCP20, and the *lacZ* transcriptional fusion plasmid pCE36 was integrated into the tyrosine DNA recombinase (FLP) recombination target sequence at the deleted *traF* locus ([@B16]; [@B19]). Competent cells for electroporation was prepared by washing three times with ice-cold water and electroporation buffer (10% glycerol) at an optical density of 0.6 (OD~600~). 200 ng DNA was mixed with 50 μL of competent cells for electroporation at 25 μF, 200Ω, and 2.5 kV. Primer sequences can be seen in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}.

Transposon Mutant Library Generation
------------------------------------

A transposon library was generated by electroporation of the EZ-Tn5^TM^ transposome into MG1655/pTF2 Δ*traF*:*lacZ*. EZ-Tn5^TM^ transposome complexes were formed between an EZ-Tn5^TM^ transposon (Epicenter) and EZ-Tn5^TM^ transposase (Epicenter), carrying a trimethoprim resistance marker to serve as a selection marker for transposon mutants. One μL of the EZ-Tn5^TM^ transposome was used for electroporation and bacteria were plated on LB agar plates containing 10 mg/L Tmp. Totally, 2 × 10^4^ transposon mutants were separated on the plates. The transposon library was stored as 30% glycerol stocks at −80°C.

Screening of Transposon-Library
-------------------------------

The transposon-library was plated on LB agar plates containing CTX (32 mg/L) and X-gal (80 mg/L) and screened for white/light blue colonies, corresponding to absence of CTX induced up-regulation of *traF*.

β-Galactosidase Assay
---------------------

β-galactosidase assays were carried out according to the method of [@B31]. Overnight cultures were diluted 100 fold in LB broth and allowed to grow at 37°C. Two experiments were performed: (i) β -galactosidase activity at different optical density: MG1655/pTF2 Δ*traF*:*lacZ* cultures with and without CTX were grown at 37°C and 2 mL samples were collected at OD~600~ = 0.1, 0.3, 0.5, 0.7, 0.9, 1.1, 1.3, and 1.5; (ii) β -galactosidase assay of wild-type (MG1655/pTF2 Δ*traF*:*lacZ)* and transposon-mutants at OD~600~ = 0.5: MG1655/pTF2 Δ*traF*:*lacZ* and the seven transposon-mutants were grown with and without CTX to OD~600~ = 0.5 and 2 mL samples were collected. All samples were immediately cooled down and centrifuged for 3 min at 8000 rpm. Pellets were resuspended in 1 mL 100 mM Z-buffer (PH 7.0), permeabilized by adding 25 μL 0.1% (W/V) SDS and 50 μL chloroform and mixed by vortexing and incubated 5 min at room temperature. β-galactosidase assay was performed using 200 μL ONPG (4 mg/mL) (o-nitrophenyl-β-D-galactopyranoside) in Z-buffer. Samples were incubated at room temperature and when color change was observed, the reactions were terminated by the addition of 500 μL of 1 M Na~2~CO~3~. OD~420~ and OD~550~ was measured, and activity calculated in Miller-units = 1000 × (OD~420~-(1.75 × OD~550~))/(T × V × OD~600~). Data correspond to three independent assays conducted in duplicate, and all values are the mean ± S.D.

Transposon Site Identification
------------------------------

Genomic DNAs were isolated from mutants using the MasterPure^TM^ complete DNA purification Kit (Epicenter) according to the instructions of the supplier. The identification of the transposon insertion site was done by whole genomic sequencing in an Illumina MiSeq (Illumina, Inc., San Diego, CA, United States) at a 300-bp paired-end-read format. Sequencing reads were *de novo* assembled using the SPAdes v.3.5.0 ([@B7]). Transposon insertions sites were identified using BLAST in CLC Main Workbench 8.0.0 (CLC bio, Denmark), and the locations of the transposon inserts were determined by a blastn comparison with the sequence of *E. coli* K-12 MG1655 (accession number [U00096.3](U00096.3)) ([@B1]).

Targeted Deletion Mutagenesis
-----------------------------

Site specific gene deletion in MG1655/pTF2 was done by insertion of kanamycin cassettes by the Lambda red recombinase system ([@B18]). Insertions were confirmed by PCR. The kanamycin cassette was then removed from the seven Kam^R^ mutants using pCP20 as previously described ([@B18]). Primers used for generating and confirming mutations are listed in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}.

RNA Extraction and RT-qPCR
--------------------------

Single colonies of MG1655/pTF2 and the seven deletion mutants were grown overnight in LB media at 37°C. The cultures were diluted 1000 fold and grown with and without 1/2 MIC of CTX to OD~600~ = 0.5. A FastPrep cell disrupter system (Qbiogene, Illkirch, France) and RNeasy Mini Kit (Qiagen, Sollentuna, Sweden) was used to extract total RNA. RNA quantity was determined by NanoDrop 1000 spectrophotometer (Thermo Scientific, Hvidovre, Denmark). Genomic DNA was removed by TURBOTM DNase kit (2 U/μL) (Ambion, Life Technologies, Nearum, Denmark). Purified RNA was reverse-transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Life Technologies, Naerum, Denmark). RT-qPCR was performed using FastStart Essential DNA Green Master (Roche, Hvidovre, Denmark) and a LightCycler 96 (Roche, Hvidovre, Denmark) as described by [@B35]. *gapA* and *nusG*, which have previously been validated, were used as reference genes ([@B25]). RT-qPCR was performed twice on separate biological samples and the results were calculated by the 2^--ΔΔCt^ method. Primer sequences can be seen in [Supplementary Table S1](#TS1){ref-type="supplementary-material"}.

Growth Experiment
-----------------

Growth of MG1655/pTF2 and deletion mutants was evaluated without and with 1/2 MIC CTX. Growth curves were obtained in biological triplicate using the automated microbiology growth curve analysis system Bioscreen C^TM^ (Oy Growth Curves Ab Ltd, Finland). A final volume of 200 μL LB broth was inoculated with cells from overnight cultures to a final cell density of 5 × 10^5^ cfu/mL, using a Sensititre^TM^ Nephelometer (Thermo Scientific^TM^, Roskilde, Denmark) with a 0.5 McFarland turbidity standard. The OD~600~ was measured every 15 min with continuous shaking for 24 h at 37°C. OD values of blank samples were subtracted from sample OD values at the respective time points before analyzing the data.

Conjugation Experiments
-----------------------

MG1655/pTF2 and deletion mutants were used as donors and *E. coli* J53-2 as recipient strain in the conjugation experiments aiming to determine the effect of targeted genes deletion on conjugational transfer rate. MG1655/pTF2 and its mutants were grown in LB media without and with 1/2 MIC of CTX to exponential phase (OD~600~ = 0.5). Antibiotics were removed by a washing steps and conjugation was performed by mixing donor and recipient strain in a 1:1 ratio on filters (0.22 μM, Millipore, Copenhagen, Denmark) on LB agar plates at 37°C for 30 and 60 min as previously described ([@B33]). The bacterial material was washed from the filters using isotonic NaCl and plated on LB agar plates containing 2 mg/L CTX (for quantifying donor + transconjugants) or 50 mg/L rifampicin and 2 mg/L CTX (quantifying transconjugants only) and incubated overnight at 37°C. The conjugation frequency was calculated as transconjugants divided by number of donors. The conjugation experiments were performed in three biological duplicates with three technical replicates each.

Statistical Analyses
--------------------

Statistical analysis was performed using the GraphPad Prism (GraphPad Software) version 7.03. Comparisons of gene expression and conjugation frequencies with and without antibiotics were performed by student's *t*-test with Welch's correction. A *P*-value of ≤0.05 was considered statistically significant.

Results
=======

Identifying Genes Involved in CTX-Induced *traF* Expression
-----------------------------------------------------------

Our previous work have reported that the transfer genes and proteins involved in conjugation of the *bla*~CTX--M--1~ plasmid pTF2 were significantly up-regulated when *E. coli* MG1655/pTF2 was treated with 1/2 MIC (126 mg/L) concentrations of CTX during growth ([@B33]). In order to identify genes involved in the mechanism by which CTX influence the Type IV secretion system (T4SS) and hence conjugation, MG1655/pTF2 Δ*traF*:*lacZ*, containing a LacZ reporter fused to the *traF* promoter, was constructed. Growing this strain with CTX on X-gal plates led to dark blue colonies, revealing high expression of *traF* during CTX exposure. A transposon library of MG1655/pTF2 Δ*traF*:*lacZ* with random Tmp-resistant Tn5 transposon insertions was screened on CTX and X-gal for lighter blue colonies, to identify genes involved in the CTX induced *traF* induction. A total of 14 light blue colonies were isolated.

In order to identify the transposon insert site, whole genome sequencing was performed on these 14 light blue mutants. Totally eight different insertion sites were identified, six of them located on the chromosome \[*rfaH* (one isolate), *yhiN* (one isolate), *waaP* (six isolates in two different positions), *waaQ* (two identical isolates), *gnd* (one isolate), and *pgl* (two identical isolates)\] and one on the plasmid \[IS*Ecp1* (one isolate)\] ([Table 2](#T2){ref-type="table"} and [Supplementary Figure S1](#TS1){ref-type="supplementary-material"}).

###### 

CTX responsive genes and their products.

  ----------------------------------------------------------------------------------------------------------------
  **Gene**   **Product**                                  **Transposon insertion site^∗^**   **Gene access no.**
  ---------- -------------------------------------------- ---------------------------------- ---------------------
  *rfaH*     Transcription antiterminator                 82/83                              M94889.1

  *yhiN*     Putative FAD/NAD(P)-binding oxidoreductase   42/43                              NC_000913.3

  *waaP*     LPS core heptose (I) kinase                  434/435\                           NC_000913.3
                                                          683/684                            

  *waaQ*     LPS core heptosyltransferase III             607/608                            NC_000913.3

  *gnd*      6-phosphogluconate dehydrogenase             757/758                            NC_000913.3

  *pgl*      6-phosphogluconolactonase                    850/851                            NC_000913.3

  IS*Ecp1*   IS*Ecp1* transposase                         973/974                            KJ563250
  ----------------------------------------------------------------------------------------------------------------

∗

Numbers refer to the base-position of the gene, between which the transposon has inserted.

To confirm the reduced expression from the *traF* promoter, a β-galactosidase assay was performed, with and without CTX, using MG1655/pTF2 Δ*traF*:*lacZ* and the 7 transposon mutants. Measuring the changes in expression during growth, showed that the β-galactosidase level in MG1655/pTF2 Δ*traF*:*lacZ* was increased significantly from OD~600~ = 0.5 by CTX treatment ([Figure 1A](#F1){ref-type="fig"}). Measuring the LacZ expression from MG1655/pTF2 Δ*traF*:*lacZ* and the seven transposon-mutants at OD~600~ = 0.5 revealed that CTX did not induce the *traF* promoter in the mutants, confirming the results from the transposon screen ([Figure 1B](#F1){ref-type="fig"}).

![β-galactosidase activity increases in MG1655/pTF2 Δ*traF*:*lacZ* during CTX exposure, but not in the transposon-mutants. **(A)** LacZ expression of MG1655/pTF2 Δ*traF*:*lacZ* with (square) and without (Circle) CTX during growth. **(B)** LacZ expression of MG1655/pTF2 Δ*traF*:*lacZ* (WT) and the seven transposon-mutants without (squared bars) and with 1/2 MIC CTX (black bars) exposure at OD~600~ = 0.5. All experiments were carried out in triplicate, and each value is presented as the average plus standard deviation. The star indicates statistical significance between antibiotic treated and untreated at level: ^∗^*P* ≤ 0.05.](fmicb-10-02203-g001){#F1}

Individual deletions of the seven identified genes were constructed in MG1655/pTF2. In order to investigate whether the deletions had an impact on CTX resistance and on bacterial growth, the MIC of CTX for the mutants was determined and the growth pattern of the strains with and without 1/2 MIC CTX was investigated. The MIC of CTX for Δ*yhiN* and Δ*gnd* corresponded to the MIC of the wild-type (MG1655/pTF2), while MIC for Δ*rfaH*, Δ*waaP*, Δ*waaQ*, and Δ*pgl* decreased two fold from 256 mg/L to 128 mg/L and ΔIS*Ecp1* decreased seven fold from 256 mg/L to 4 mg/L. Without CTX exposure, the strains showed a similar growth pattern, however, when exposed to CTX (1/2 MIC of the corresponding strain), the Δ*rfaH*, Δ*waaP*, Δ*waaQ*, and Δ*pgl* showed decreased length of lag phase compared to MG1655/pTF2 ([Figure 2](#F2){ref-type="fig"}). However, since all expression and conjugation experiments were performed with bacteria grown to the same OD, the variations in lag-phase were not expected to influence the obtained results.

![Growth phenotypes of MG1655/pTF2 and its mutants with and without CTX. All strains were grown without and with CTX (1/2 MIC of the corresponding strain). Three independent replicates were performed and the data shown represent the mean and dots represent standard deviations.](fmicb-10-02203-g002){#F2}

To confirm the importance of the genes in CTX induced *traF* regulation, we used RT-qPCR analysis, and found a significant up-regulation of *traF* (6.1-fold, *t*-test, *P* = 0.01) when the wild-type strain (MG1655/pTF2) was treated with CTX. In contrast, and in support of the β-galactosidase assay results, none of the deletion mutants showed significant CTX induced *traF* up-regulation ([Figure 3](#F3){ref-type="fig"}).

![CTX induced expression of the *traF* gene in WT (MG1655/pTF2) and deletion mutants. Strains were grown with 1/2 MIC CTX or without. Data are presented as fold change in CTX induced expression relative to expression levels without CTX. Three independent replicates including two technical replicates each were performed. The data shown represents the mean and the error bars represent standard deviations. The expression data was normalized to *gapA* and *nusG*. The stars indicate statistical significance between the two conditions at level: ^∗^*P* ≤ 0.05.](fmicb-10-02203-g003){#F3}

CTX-Induced *bla*~CTX--M--1~ Expression
---------------------------------------

We have previously reported that the induction of transfer gene-expression and increased conjugation frequency by treatment with CTX is dependent on the presence of the antibiotic resistance gene *bla*~CTX--M--1~ ([@B33]). To investigate whether the identified seven genes also work in a CTX-M-1 dependent manner to regulate the CTX-induced increased conjugation, we performed RT-qPCR. We found that the *bla*~CTX--M--1~ gene expression was significantly up-regulated (6.56- fold, *t*-test, *P* = 0.03) in the wild-type strain during CTX treatment, whereas CTX exposure had limited, non-significant, effect on *bla*~CTX--M--1~ expression in the seven knock-out mutants ([Figure 4](#F4){ref-type="fig"}) and the seven isolated transposon-mutants (data not shown). Expression of *bla*~CTX--M--1~ was not significantly different between the mutants and the wild-type, when the strains were not exposed to CTX ([Supplementary Figure S2](#TS1){ref-type="supplementary-material"}).

![CTX induced expression of *bla*~CTX--M--1~ in WT (MG1655/pTF2) and deletion mutants. Strains were grown with 1/2MIC CTX or without. Data are presented as fold change in CTX induced expression relative to expression levels without CTX. Two independent replicates including two technical replicates each were performed. The data shown represents the mean and the error bars represent standard deviations. The expression data was normalized to two validated reference genes, *gapA* and *nusG*. The stars indicate statistical significance at level: ^∗^*P* ≤ 0.05.](fmicb-10-02203-g004){#F4}

CTX-Induced Expression of Selected Gene in Wild-Type and Δ*rfaH* Mutant
-----------------------------------------------------------------------

In order to investigate whether the genes identified by transposon mutagenesis were regulating *tra* gene expression independent of CTX or not, RT-qPCR was performed to investigate the expression of the seven genes in the wild-type strain, comparing expression between CTX treated and untreated wild-type. Significant up-regulation of *rfaH* (2.7- fold, *t*-test, *P* = 0.03), *yhiN* (4.8- fold, *t*-test, *P* = 0.02), *waaQ* (5.2- fold, *t*-test, *P* = 0.03) and *gnd* (5.1- fold, *t*-test, *P* = 0.006) was observed, when the wild-type was treated with 1/2 MIC of CTX during growth. For the *waaP* and *pgl* genes, a non-significant, 5.9- and 5.6- fold (*t*-test, *P* \> 0.05) increase in gene expression was observed. The data showed that CTX do up-regulate the expression of these genes, except the IS*Ecp1* ([Figure 5](#F5){ref-type="fig"}, black bars). In addition, we investigated the expression level of the individual genes in the *rfaH* mutant background, to evaluate a possible regulatory link between RfaH and the remaining genes. Only *yhiN* (2.0- fold, *t*-test, *P* = 0.01) and *pgl* (2.9- fold, *t*-test, *P* = 0.03) showed significant up-regulation when Δ*rfaH* was treated with CTX during growth, however, not to the level observed in the wild-type ([Figure 5](#F5){ref-type="fig"}, squared bars).

![CTX induces expression of six genes involved in antibiotic induced *traF* expression in MG1655/pTF2. MG1655/pTF2 (Black bars) and the Δ*rfaH* (squared bars) were grown with 1/2 MIC CTX or without. Data are presented as fold change in CTX induced expression relative to expression levels without CTX. Three independent replicates including two technical replicates each were performed. The data shown represents the mean and the error bars represent standard deviations. The expression data was normalized to *gapA* and *nusG*. The stars indicate statistical significance at different levels: ^∗^*P* ≤ 0.05, ^∗∗^*P* ≤ 0.01.](fmicb-10-02203-g005){#F5}

CTX-Induced Conjugative Plasmid Transfer
----------------------------------------

In order to investigate whether the deletion of the seven genes would affect the number of CTX-induced conjugation events, conjugation experiments was performed with the wild-type (MG1655/pTF2) and the mutants, pre-grown with or without CTX. The data showed that the CTX treatment significantly increased plasmid transfer frequency in MG1655/pTF2 with 25.0- and 41.0- fold (*t*-test, *P* ≤ 0.05) after 30 and 60 min of cell contact, relative to conjugation without pre-growth in the presence of CTX ([Table 3](#T3){ref-type="table"}). In contrast, all of the mutants revealed a decreased CTX-induced plasmid transfer compared to the wild-type. We did not obtain any transconjugants for ΔIS*Ecp1* probably due to transfer frequencies below detection limit.

###### 

Fold changes of CTX-induced (1/2 MIC) increased conjugation transfer frequency, relative to untreated strains, using MG1655/pTF2 (WT) and the mutants as donors and J53-2 as recipient.

  **Donor**   **Conjugation time (min)**   **Conjugation transfer frequency (Control)^a^**   **Conjugation transfer frequency (CTX)^a^**   **Plasmid transfer fold difference^b^**
  ----------- ---------------------------- ------------------------------------------------- --------------------------------------------- -----------------------------------------
  WT          30                           3.90 × 10^--5^ ± 1.05 × 10^--5^                   9.75 × 10^--4^ ± 1.46 × 10^--4^               25.00^∗∗^
              60                           3.00 × 10^--4^ ± 0.49 × 10^--4^                   1.23 × 10^--2^ ± 0.34 × 10^--2^               41.00^∗^
  Δ*rfaH*     30                           1.13 × 10^--5^ ± 0.32 × 10^--5^                   0.87 × 10^--5^ ± 0.26 × 10^--5^               0.77
              60                           1.14 × 10^--4^ ± 0.12 × 10^--4^                   1.06 × 10^--4^ ± 0.39 × 10^--4^               0.93
  Δ*yhiN*     30                           2.48 × 10^--5^ ± 0.96 × 10^--5^                   3.64 × 10^--4^ ± 0.39 × 10^--4^               14.68^∗∗^
              60                           5.25 × 10^--4^ ± 1.24 × 10^--4^                   2.86 × 10^--3^ ± 0.60 × 10^--3^               4.50^∗^
  Δ*waaP*     30                           2.33 × 10^--5^ ± 0.65 × 10^--5^                   3.46 × 10^--4^ ± 0.72 × 10^--4^               14.85^∗^
              60                           3.29 × 10^--4^ ± 0.79 × 10^--4^                   3.09 × 10^--3^ ± 0.97 × 10^--3^               9.57
  Δ*waaQ*     30                           2.97 × 10^--5^ ± 1.04 × 10^--5^                   3.23 × 10^--5^ ± 0.67 × 10^--5^               1.09
              60                           2.73 × 10^--4^ ± 0.60 × 10^--4^                   4.47 × 10^--3^ ± 1.44 × 10^--3^               16.37
  Δ*gnd*      30                           2.44 × 10^--5^ ± 0.64 × 10^--5^                   3.16 × 10^--4^ ± 0.65 × 10^--4^               12.95^∗^
              60                           3.59 × 10^--4^ ± 0.88 × 10^--4^                   5.47 × 10^--3^ ± 0.4707 × 10^--3^             15.24^∗∗^
  Δ*pgl*      30                           1.16 × 10^--5^ ± 0.24 × 10^--5^                   1.26 × 10^--4^ ± 0.24 × 10^--4^               10.86^∗^
              60                           2.27 × 10^--4^ ± 0.48 × 10^--4^                   2.31 × 10^--3^ ± 0.41 × 10^--3^               10.18^∗^

a

The results shown are from two biological replicates with three technical replicates each, the data shown represent the mean ± standard deviation.

b

The stars indicate statistical significance at level:

∗

P

≤ 0.05,

∗∗

P

≤ 0.01.

Discussion
==========

The contribution of antibiotics as a stimulating factor to the promotion of conjugation transfer has previously been investigated ([@B9]; [@B4]; [@B20]; [@B30]; [@B33]). However, despite our current knowledge that antibiotics can increase conjugation frequency, it still remains unclear which mechanisms are involved in this phenomenon. We have previously obtained evidence that 1/2 MIC concentrations of CTX affects expression of the conjugation apparatus of plasmid pTF2, as *tra*-genes were significantly up-regulated at both the transcriptional and translational level ([@B33]). *traF* is one of several T4SS proteins involved in pilus assembly and essential for plasmid transfer ([@B21]). In the current study, a *traF*:*lacZ* reporter gene-fusion was constructed, to enable a screening for genes which affect the antibiotic induced up-regulation of *traF* expression. Random insertional mutagenesis mediated by Tn5 transposon was carried out in the reporter strain and in total seven genes were identified (*rfaH*, *yhiN*, *waaP* (*rfaP*), *waaQ* (*rfaQ*), *gnd*, and *pgl* and the pTF2 plasmid-encoded insertion sequence IS*Ecp1*) where knock-out by transposon insertion abolished the CTX induced up-regulation of *traF*.

RfaH is a transcriptional antiterminator, which activates operons encoding lipopolysaccharide (LPS) core components, pili, toxins, capsules and antibiotic biosynthesis in *Enterobacteriaceae* ([@B37]; [@B6]; [@B34]). Furthermore, reduced plasmid transfer has been shown for a *Salmonella Typhimurium rfaH* mutant ([@B37]). A possible explanation for CTX induced up-regulation of *traF* is therefore that CTX treatment increases the expression of *rfaH*, and this activates the expression of pilus encoding genes, such as *traF*. A previous study has shown RfaH binding to an ops element in the promoter region of the *tra* operon on the F plasmid ([@B5]). Sequence analysis revealed an ops element in the *tra* promoter region on pTF2 (IncI1 plasmid), supporting direct RfaH regulation of *traF* expression. Furthermore, we showed that CTX induce *rfaH* and *traF* expression, however, the latter not in a *rfaH* knock out background, and thus that the CTX induction of the *traF* expression is dependent on RfaH. The *waaP* and *waaQ* genes, which are regulated by RfaH, play important roles in LPS biosynthesis and the formation of a stable outer membrane ([@B43]; [@B10]). Mutations in the *waa* locus can significantly alter outer membrane permeability and hypersensitivity to detergents and hydrophobic antibiotics ([@B38]). *gnd* and *pgl* are two enzymes of the oxidative branch of the hexose monophosphate shunt in the pathway of glucose metabolism ([@B27]). It is unknown how *gnd* and *pgl* regulate *tra* expression, but *gnd* is adjacent to a RfaH-regulated transcription unit, suggesting RfaH affects expression of *gnd* ([@B10]). The *yhiN* gene is a putative FAD/NAD(P) binding oxidoreductase with unknown function. It is part of the RpoS regulon, indicating an importance in the stress response ([@B40]). Previously published results have shown that high levels of RpoS affect conjugative transfer in *Pseudomonas knackmussii* ([@B32]). The *bla*~CTX--M~ genes are often associated with IS*Ecp1*-like elements ([@B24]; [@B8]; [@B13]; [@B36]). These elements contain putative -35 and -10 promoter regions within the 3′ end of IS*Ecp1* affecting the expression level of the *bla*~CTX--M~ gene ([@B24]; [@B36]).

Deletions of the seven genes were performed in MG1655/pTF2 to evaluate their involvement in CTX induced increased plasmid transfer. For the wild-type MG1655/pTF2 we observed a significant CTX induction of expression of *traF* and *bla*~CTX--M--1~, and a significant induction of plasmid transfer. In contrast, we saw that the mutants were hampered in CTX-induced *traF* and *bla*~CTX--M--1~ expression and plasmid transfer. Results confirmed that increased *bla*~CTX--M--1~ gene expression is necessary for increased conjugation transfer frequency. We have previously shown that exposing a *bla*~CTX--M--1~ mutant of MG1655/pTF2 to CTX did not lead to induced *tra* gene expression and plasmid transfer ([@B33]). Furthermore, when exposed to CTX, the ΔIS*Ecp1* mutant expressed very low levels of *bla*~CTX--M--1~, as seen from the MIC, and was unable to induce *traF* expression. IS*Ecp1*-like elements have been shown to contain promoter sequences for high level expression of *bla*~CTX--M~ β-lactamase genes ([@B36]); probably explaining why we observed limited CTX induced expression of *bla*~CTX--M--1~. The IS*Ecp1* most likely is not part of the CTX induced conjugation pathway, instead the deletion simply affects *bla*~CTX--M--1~ expression, supported by the severely reduced MIC, and the lack of CTX induced *traF* and *bla*~CTX--M--1~ expression.

Our results showed that the deletion of the genes resulted in reduced CTX induction of plasmid transfer compared to the wild-type (MG1655/pTF2), confirming that the *rfaH*, *yhiN*, *waaP*, *waaQ*, *gnd* and *pgl*, genes are involved in the CTX induced increased pTF2 plasmid conjugative transfer.

In order to investigate how the seven identified genes contribute to CTX induced *traF* expression, we measured whether the genes themselves were regulated by CTX. We found that the expression of the *rfaH*, *yhiN*, *waaQ*, and *gnd* genes in the wild-type indeed were up-regulated significantly in the presence of CTX, and the expression of *waaP* and *pgl* was also up-regulated, although not significant. Only expression of IS*Ecp1* was not affected by CTX. This CTX-induced up-regulation of *waaP*, *waaQ*, and *gnd* disappeared in an *rfaH* mutant background, and the CTX induced expression of *yhiN* and *pgl* was decreased in the Δ*rfaH* strain compared to the expression levels in the wild-type background. These results support that RfaH is central not only in the regulation of these five genes, but also in the CTX induction of conjugation. Thus our current model is that CTX induce *bla*~CTX--M--1~ expression as well as *rfaH* expression. This affects *tra* expression directly as well as through changed expression of the *waaP*, *waaQ*, *gnd, yhiN*, and *pgl* genes, which affect *bla*~CTX--M--1~ expression and hence *traF* expression.

Conclusion
==========

In conclusion, six genes involved in CTX induced increased conjugation have been identified. Further experiments are needed to uncover the role of these genes in the pathways by which bacteria sense CTX and signals induced *tra* expression.
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